{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:16:54Z","timestamp":1774419414971,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain Research"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.brainres.2017.08.013","type":"journal-article","created":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T04:47:10Z","timestamp":1503031630000},"page":"102-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Beneficial effects of glatiramer acetate in Huntington\u2019s disease mouse models: Evidence for BDNF-elevating and immunomodulatory mechanisms"],"prefix":"10.1016","volume":"1673","author":[{"given":"Jody","family":"Corey-Bloom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaina M.","family":"Aikin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley M.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jwan S.","family":"Nadhem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor L.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.brainres.2017.08.013_b0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1155\/2009\/267581","article-title":"Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis","volume":"27","author":"Achiron","year":"2009","journal-title":"Dis. Markers"},{"key":"10.1016\/j.brainres.2017.08.013_b0010","doi-asserted-by":"crossref","first-page":"19045","DOI":"10.1073\/pnas.0509438102","article-title":"The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice","volume":"102","author":"Aharoni","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.brainres.2017.08.013_b0015","doi-asserted-by":"crossref","first-page":"14157","DOI":"10.1073\/pnas.2336171100","article-title":"Glatiramer acetate-specific T cells in the brain express T helper 2\/3 cytokines and brain-derived neurotrophic factor in situ","volume":"100","author":"Aharoni","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.brainres.2017.08.013_b0020","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/jnr.21139","article-title":"Mouse and rat BDNF gene structure and expression revisited","volume":"85","author":"Aid","year":"2007","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.brainres.2017.08.013_b0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jneuroim.2005.07.001","article-title":"Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate","volume":"167","author":"Azoulay","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.brainres.2017.08.013_b0030","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1517\/14728222.2013.778829","article-title":"Gene expression analysis reveals functional pathways of glatiramer acetate activation","volume":"17","author":"Bakshi","year":"2013","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.brainres.2017.08.013_b0035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jneuroim.2009.11.016","article-title":"Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis","volume":"219","author":"Begum-Haque","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.brainres.2017.08.013_b9000","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jneuroim.2008.07.018","article-title":"Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis","volume":"204","author":"Begum-Haque","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.brainres.2017.08.013_b0040","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.neuron.2009.09.034","article-title":"Harnessing immune alterations in neurodegenerative diseases","volume":"64","author":"Bjorkqvist","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.brainres.2017.08.013_b0045","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease","volume":"205","author":"Bjorkqvist","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.brainres.2017.08.013_b0050","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.neulet.2006.07.043","article-title":"Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study","volume":"406","author":"Blanco","year":"2006","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.brainres.2017.08.013_b0055","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bbi.2014.09.011","article-title":"Plasma inflammatory biomarkers for Huntington's disease patients and mouse model","volume":"44","author":"Chang","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.brainres.2017.08.013_b0060","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0022-510X(03)00177-1","article-title":"Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor","volume":"215","author":"Chen","year":"2003","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.brainres.2017.08.013_b0065","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3233\/JHD-140110","article-title":"Disease modifying potential of glatiramer acetate in Huntington\u2019s disease","volume":"3","author":"Corey-Bloom","year":"2014","journal-title":"J. Huntington\u2019s Dis."},{"key":"10.1016\/j.brainres.2017.08.013_b0070","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1021\/pr0700753","article-title":"Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates","volume":"6","author":"Dalrymple","year":"2007","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.brainres.2017.08.013_b9005","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jneuroim.2006.07.014","article-title":"Glatiramer acetate-specific human CD8(+) T cells: increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment","volume":"181","author":"Dressel","year":"2006","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.brainres.2017.08.013_b0075","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1073\/pnas.0536856100","article-title":"Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice","volume":"100","author":"Duan","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.brainres.2017.08.013_b0080","doi-asserted-by":"crossref","first-page":"541259","DOI":"10.1155\/2013\/541259","article-title":"The role of the immune system in Huntington's disease","volume":"2013","author":"Ellrichmann","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.brainres.2017.08.013_b0085","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0006-8993(00)02237-X","article-title":"Brain-derived neurotrophic factor in Huntington disease","volume":"866","author":"Ferrer","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.brainres.2017.08.013_b0090","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1471-4159.2007.05137.x","article-title":"Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice","volume":"105","author":"Gharami","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.brainres.2017.08.013_b0095","doi-asserted-by":"crossref","first-page":"e64037","DOI":"10.1371\/journal.pone.0064037","article-title":"Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6\/2 mouse model of Huntington's disease","volume":"8","author":"Giampa","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.brainres.2017.08.013_b0100","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"'A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group\u2019","volume":"72","author":"Group, Huntington's Disease Collaborative Research","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.brainres.2017.08.013_b0105","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.neuroscience.2008.08.041","article-title":"Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice","volume":"157","author":"Hickey","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.brainres.2017.08.013_b0110","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1750-1326-7-12","article-title":"Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease","volume":"7","author":"Hickey","year":"2012","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.brainres.2017.08.013_b9010","doi-asserted-by":"crossref","first-page":"G628","DOI":"10.1152\/ajpgi.00137.2006","article-title":"Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis","volume":"292","author":"Horani","year":"2007","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.brainres.2017.08.013_b0115","doi-asserted-by":"crossref","first-page":"E56","DOI":"10.1073\/pnas.1415195112","article-title":"HDAC inhibition imparts beneficial transgenerational effects in Huntington\u2019s disease mice via altered DNA and histone methylation","volume":"112","author":"Jia","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.brainres.2017.08.013_b0120","doi-asserted-by":"crossref","first-page":"e0152498","DOI":"10.1371\/journal.pone.0152498","article-title":"The effects of pharmacological inhibition of histone deacetylase 3 (HDAC3) in Huntington\u2019s disease mice","volume":"11","author":"Jia","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.brainres.2017.08.013_b0125","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1586\/ern.12.25","article-title":"Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis","volume":"12","author":"Johnson","year":"2012","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.brainres.2017.08.013_b0130","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1017\/S1461145710000738","article-title":"Blood BDNF concentrations reflect brain-tissue BDNF levels across species","volume":"14","author":"Klein","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.brainres.2017.08.013_b9015","first-page":"173","article-title":"Interleukin 12 and interleukin 10 are affected differentially by treatment of multiple sclerosis with glatiramer acetate (Copaxone)","volume":"40","author":"Losy","year":"2002","journal-title":"Folia Neuropathol."},{"key":"10.1016\/j.brainres.2017.08.013_b0135","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/15321819.2011.538625","article-title":"Brain-derived neurotrophic factor in human saliva: ELISA optimization and biological correlates","volume":"32","author":"Mandel","year":"2011","journal-title":"J. Immunoassay Immunochem."},{"key":"10.1016\/j.brainres.2017.08.013_b0140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cne.10776","article-title":"Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington\u2019s disease with 140 CAG repeats","volume":"465","author":"Menalled","year":"2003","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.brainres.2017.08.013_b0145","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/jnr.23440","article-title":"Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate","volume":"92","author":"Moore","year":"2014","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.brainres.2017.08.013_b0150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.brainres.2017.08.013_b0155","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1212\/WNL.56.6.702","article-title":"Mechanisms of action of glatiramer acetate in multiple sclerosis","volume":"56","author":"Neuhaus","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.brainres.2017.08.013_b0160","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jneuroim.2012.09.009","article-title":"Glatiramer Acetate administration does not reduce damage after cerebral ischemia in mice","volume":"254","author":"Poittevin","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.brainres.2017.08.013_b0165","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.expneurol.2016.08.012","article-title":"Expression of brain-derived neurotrophic factor in astrocytes \u2013 Beneficial effects of glatiramer acetate in the R6\/2 and YAC128 mouse models of Huntington's disease","volume":"285","author":"Reick","year":"2016","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.brainres.2017.08.013_b0170","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/WNR.0b013e32832e34ee","article-title":"Distinct neuroinflammatory profile in post-mortem human Huntington\u2019s disease","volume":"20","author":"Silvestroni","year":"2009","journal-title":"Neuroreport"},{"key":"10.1016\/j.brainres.2017.08.013_b0175","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.bbi.2012.12.015","article-title":"Chronic mild stress eliminates the neuroprotective effect of Copaxone after CNS injury","volume":"31","author":"Smirnov","year":"2013","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.brainres.2017.08.013_b0180","doi-asserted-by":"crossref","first-page":"e23691","DOI":"10.1371\/journal.pone.0023691","article-title":"Genome-wide identification of Bcl11b gene targets reveals role in brain-derived neurotrophic factor signaling","volume":"6","author":"Tang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.brainres.2017.08.013_b0185","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1196\/annals.1309.055","article-title":"Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies","volume":"1029","author":"Teitelbaum","year":"2004","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.brainres.2017.08.013_b0190","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2147\/nedt.2007.3.2.259","article-title":"Glatiramer acetate in the treatment of multiple sclerosis","volume":"3","author":"Tselis","year":"2007","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.brainres.2017.08.013_b0195","doi-asserted-by":"crossref","first-page":"14708","DOI":"10.1523\/JNEUROSCI.1637-10.2010","article-title":"BDNF overexpression in the forebrain rescues Huntington\u2019s disease phenotypes in YAC128 mice","volume":"30","author":"Xie","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainres.2017.08.013_b0200","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1471-4159.2003.01980.x","article-title":"Depletion of wild-type huntingtin in mouse models of neurologic diseases","volume":"87","author":"Zhang","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.brainres.2017.08.013_b0205","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1093\/brain\/awf252","article-title":"Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor","volume":"125","author":"Ziemssen","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.brainres.2017.08.013_b0210","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1126\/science.1059581","article-title":"Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease","volume":"293","author":"Zuccato","year":"2001","journal-title":"Science"}],"container-title":["Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899317303499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899317303499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T16:59:35Z","timestamp":1602781175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006899317303499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":46,"alternative-id":["S0006899317303499"],"URL":"https:\/\/doi.org\/10.1016\/j.brainres.2017.08.013","relation":{},"ISSN":["0006-8993"],"issn-type":[{"value":"0006-8993","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beneficial effects of glatiramer acetate in Huntington\u2019s disease mouse models: Evidence for BDNF-elevating and immunomodulatory mechanisms","name":"articletitle","label":"Article Title"},{"value":"Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brainres.2017.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}